BSA-Based Stabilization of Prussian Blue-Coated Manganese Ferrite Nanoparticles for MRI

Objectives: Magnetic nanoparticles are promising candidates for T2-weighted magnetic resonance imaging (MRI), but their physicochemical stability and biological compatibility remain important challenges for biomedical applications. Methods: In this study, amine-functionalized manganese ferrite (MnFe2O4) nanoparticles were coated with Prussian blue (PB) and subsequently formulated with bovine serum albumin (BSA). The resulting formulation was characterized using X-ray diffraction, transmission electron microscopy, X-ray photoelectron spectroscopy, Fourier-transform infrared spectroscopy, magnetic measurements, dynamic light scattering, molecular dynamics simulations, cytocompatibility assays, and MRI relaxometry. Results: The BSA-formulated nanoparticles were readily redispersed after lyophilization and remained colloidally stable throughout the 6 h observation period in the tested aqueous media. Molecular dynamics simulations demonstrated persistent close contacts between the MnFe2O4 surface and BSA residues, supporting stable nanoparticle–protein association. MRI relaxometry showed predominantly T2-weighted contrast behavior, with substantially higher r2 than r1 relaxivity. In vitro metabolic activity measurements demonstrated higher relative metabolic activity for the PB-coated formulation than for the corresponding uncoated formulation within the BSA-formulated systems. A pilot in vivo MRI experiment performed in a single mouse demonstrated rapid hepatic accumulation, with a detectable reduction in liver signal intensity within 10 min after administration and persistence of the hepatic signal change at the following-day measurement. Conclusions: These preliminary findings support further investigation of BSA-formulated PB-coated MnFe2O4 nanoparticles as a potential T2-weighted MRI contrast platform.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-09-24
DOI
https://doi.org/10.3390/pharmaceutics18101217
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

BSA-Based Stabilization of Prussian Blue-Coated Manganese Ferrite Nanoparticles for MRI

Krisztián Szigeti, Miklós Németh, Béla Viskolcz, Ágnes Mária Ilosvai et al.
Pharmaceutics
Nanoparticle-Based Drug Delivery
article

BSA-Based Stabilization of Prussian Blue-Coated Manganese Ferrite Nanoparticles for MRI

Krisztián Szigeti, Miklós Németh, Béla Viskolcz, Ágnes Mária Ilosvai, Ferenc Kristály, László Forgách, Fatemeh Heydari, Babak Minofar, Lajos Daróczi, László Vanyorek, Tamás Ollár, Noémi Kovács, David Reha
article en

Abstract

Objectives: Magnetic nanoparticles are promising candidates for T2-weighted magnetic resonance imaging (MRI), but their physicochemical stability and biological compatibility remain important challenges for biomedical applications. Methods: In this study, amine-functionalized manganese ferrite (MnFe2O4) nanoparticles were coated with Prussian blue (PB) and subsequently formulated with bovine serum albumin (BSA). The resulting formulation was characterized using X-ray diffraction, transmission electron microscopy, X-ray photoelectron spectroscopy, Fourier-transform infrared spectroscopy, magnetic measurements, dynamic light scattering, molecular dynamics simulations, cytocompatibility assays, and MRI relaxometry. Results: The BSA-formulated nanoparticles were readily redispersed after lyophilization and remained colloidally stable throughout the 6 h observation period in the tested aqueous media. Molecular dynamics simulations demonstrated persistent close contacts between the MnFe2O4 surface and BSA residues, supporting stable nanoparticle–protein association. MRI relaxometry showed predominantly T2-weighted contrast behavior, with substantially higher r2 than r1 relaxivity. In vitro metabolic activity measurements demonstrated higher relative metabolic activity for the PB-coated formulation than for the corresponding uncoated formulation within the BSA-formulated systems. A pilot in vivo MRI experiment performed in a single mouse demonstrated rapid hepatic accumulation, with a detectable reduction in liver signal intensity within 10 min after administration and persistence of the hepatic signal change at the following-day measurement. Conclusions: These preliminary findings support further investigation of BSA-formulated PB-coated MnFe2O4 nanoparticles as a potential T2-weighted MRI contrast platform.

PharmaceuticsVol. 18(10)
Semmelweis University (HU), University of Debrecen (HU), VSB - Technical University of Ostrava (CZ), University of Miskolc (HU), University of Łódź (PL), HUN-REN Centre for Energy Research (HU)
Openalex Percentile: Top 22%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.